XOMA Corporation (Nasdaq: XOMA) today announced it has initiated dosing in its Phase 1 study exploring the safety and tolerability ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE